Atara Biotherapeutics(ATRA) - 2024 Q4 - Annual Results

Financial Position - Atara Biotherapeutics reported cash, cash equivalents, and short-term investments as of December 31, 2024, but specific figures were not disclosed in the preliminary estimate[6] Product Update - The company provided a regulatory and business update on its product EBVALLO™ (tabeleucel) on January 16, 2025[7]